Scope
NICE guideline NG238 covers cardiovascular disease (CVD) risk assessment and reduction, including lipid modification, with recommendations dated up to December 2023. It addresses systematic identification and QRISK3-based risk assessment for people without CVD, including groups in whom risk tools should not be used or may underestimate risk. It also covers risk communication, lifestyle advice, aspirin, lipid testing thresholds for specialist referral and assessment before starting statins. Further sections cover statin use and lipid goals for primary prevention, including type 1 diabetes, chronic kidney disease and people aged 85 or older, and for secondary prevention. The remaining sections cover non-statin escalation, statin intolerance, monitoring and lipid-lowering agents that should not be used.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Identifying and assessing CVD risk in people without CVD
- Primary care should use a systematic strategy to identify people likely to be at high CVD risk. Opportunistic assessment of unselected people should not be the main strategy. Prioritise people with an estimated 10-year risk of 10% or more for full formal assessment. [1]
- Use QRISK3 to estimate 10-year CVD risk in people aged 25 to 84 without CVD, including those with type 2 diabetes. QRISK2 may be needed temporarily until clinical systems are updated. However, use QRISK3 for people taking corticosteroids or atypical antipsychotics and for people with systemic lupus erythematosus, migraine, severe mental illness or erectile dysfunction. QRISK2 does not account for these factors and may underestimate their 10-year risk. [1]
- Do not apply a risk tool to people already at high risk. This includes people with type 1 diabetes, people with an eGFR below 60 ml per minute per 1.73 m2 and/or albuminuria, and people with familial hypercholesterolaemia or other inherited lipid disorders. [1]
- Risk tools may underestimate risk in some groups. Examples include people treated for HIV, people taking drugs that can cause dyslipidaemia such as immunosuppressants, and people with autoimmune or other systemic inflammatory disorders. [1]
Risk communication, lifestyle and aspirin
- Offer information on absolute 10-year risk and on the absolute benefits and harms of interventions. Consider a lifetime risk tool such as QRISK3-lifetime to support discussion and motivate lifestyle change, particularly when the 10-year QRISK3 score is below 10% or the person is under 40 with risk factors. If someone declines recommended treatment, advise that their risk should be reassessed in future. [1]
- Aspirin should not be routinely offered for primary prevention of CVD. [1]
- For people at high risk of or with CVD, advise total fat intake of 30% or less and saturated fat of 7% or less of total energy intake. Where possible, saturated fats should be replaced with unsaturated fats. Also advise aerobic and muscle-strengthening activity in line with national guidance, and support smoking cessation. [1]
Lipid measurement and specialist referral
- Exclude common secondary causes of dyslipidaemia before referral. Arrange specialist assessment for total cholesterol above 9.0 mmol per litre or non-HDL cholesterol above 7.5 mmol per litre. Refer urgently for triglycerides above 20 mmol per litre that are not explained by excess alcohol intake or poor glycaemic control. For triglycerides of 10 to 20 mmol per litre, take three steps: repeat the test fasting after 5 days but within 2 weeks, review for potential secondary causes of hyperlipidaemia, and seek specialist advice if the level stays above 10 mmol per litre. [1]
Assessment before starting statins
- Decide on statins through informed discussion. Take account of potential lifestyle benefit, preferences, comorbidity, polypharmacy, frailty and life expectancy. Advise people that the risk of muscle symptoms is small and that rhabdomyolysis is extremely rare. [1]
- Complete baseline blood tests and a clinical assessment, including a full lipid profile, renal function and transaminases. Transaminases that are raised but below 3 times the upper limit of normal should not routinely exclude statin use. [1]
- Ask about persistent unexplained generalised muscle symptoms and check creatine kinase if they are present. If creatine kinase is more than 5 times the upper limit of normal, re-measure it after 7 days. Do not start statin treatment if creatine kinase is still 5 times the upper limit of normal after 7 days. If it is raised but below 5 times the upper limit of normal, start at a lower dose. [1]
- Statins are contraindicated in pregnancy. Explain that statins should be stopped if pregnancy is possible and 3 months before trying to conceive. They should not be restarted until breastfeeding has finished. [1]
Lipid-lowering for primary prevention
- Before offering a statin, discuss lifestyle change and optimise other modifiable risk factors. Offer a statin if lifestyle change is ineffective or inappropriate. Offer atorvastatin 20 mg at a 10-year QRISK3 score of 10% or more. Do not rule it out below 10% if the person has an informed preference or risk may be underestimated. Aim for a greater than 40% reduction in non-HDL cholesterol. [1]
- People aged 85 or older are considered at increased risk from age alone, especially if they smoke or have raised blood pressure. Atorvastatin 20 mg can be considered, while weighing factors that may make treatment inappropriate. [1]
- In type 1 diabetes, offer statins to adults who are older than 40 years, have had diabetes for more than 10 years, have established nephropathy or have other risk factors. Consider statins for people aged 18 to 40, including those who have had diabetes for 10 years or less. Start with atorvastatin 20 mg. [1]
- In CKD, offer atorvastatin 20 mg for primary or secondary prevention. Increase the dose if the primary or secondary prevention lipid target is not met and eGFR is 30 ml per minute per 1.73 m2 or more. If eGFR is below 30, agree higher doses with a renal specialist. [1]
Lipid-lowering for secondary prevention
- Offer atorvastatin 80 mg to people with CVD regardless of cholesterol level. Offer a lower dose if there is a risk of drug interaction, a high risk of adverse effects, or the person prefers a lower dose. In acute coronary syndrome, do not delay statins, and measure a full lipid profile on admission and 2 to 3 months after starting. [1]
- The secondary prevention lipid goal is LDL cholesterol of 2.0 mmol per litre or less, or non-HDL cholesterol of 2.6 mmol per litre or less. [1]
- If the goal is not reached on the maximum tolerated statin, consider adding an option recommended in technology appraisal guidance: alirocumab, evolocumab, ezetimibe or inclisiran. Ezetimibe may also be considered in addition to the maximum tolerated statin even when the goal is met. [1]
- Offer ezetimibe instead of a statin when statins are contraindicated, or when no statin can be tolerated after documented discussion of tolerance strategies. If the goal is not met on ezetimibe, consider alternative or additional options recommended in technology appraisal guidance, such as bempedoic acid with ezetimibe or inclisiran. [1]
Optimising, monitoring and agents not recommended
- When the primary or secondary prevention lipid target is not met, review adherence and the timing of the statin dose. Consider increasing statin intensity or dose if the person is not on a high-intensity statin at the maximum tolerated dose. For adverse effects on a high-intensity statin, discuss options such as switching from atorvastatin to rosuvastatin. Advise that any statin at any dose lowers CVD risk. [1]
- Check transaminases and a full lipid profile 2 to 3 months after starting or changing therapy. Check transaminases again at 12 months, then only if clinically indicated. Provide annual medication reviews. Offer an annual full lipid profile for secondary prevention and consider one for primary prevention. [1]
- Measure creatine kinase in people on statins who develop unexplained muscle symptoms, but not in asymptomatic people. If creatine kinase is below 5 times the upper limit of normal, reassure them and look for other causes. Do not stop statins because blood glucose or HbA1c rises. [1]
- For CVD prevention, fibrates are not routinely offered. Nicotinic acid and bile acid sequestrants are not offered. Omega-3 fatty acid compounds are also not offered, except icosapent ethyl used as described in its technology appraisal. [1]
Limitations and use
- Familial hypercholesterolaemia is managed through NICE's separate guideline on that condition. The recommendations on lipid-lowering agents that should not be used do not apply to this group.
- People on renal replacement therapy are outside the scope of this guideline.
- QRISK3 is intended only for people aged 25 to 84. No risk tool is available for people aged 85 or older.
- Several escalation and statin-intolerance recommendations defer to separate NICE technology appraisals (ezetimibe, bempedoic acid with ezetimibe, alirocumab, evolocumab, inclisiran and icosapent ethyl). Their detailed eligibility criteria are not reproduced here.
- The source notes that lower-dose atorvastatin for secondary prevention was an off-label use in December 2023.
- Research recommendations and committee or update-history chapters were not part of the reviewed source. Flowcharts were available only as alternative text.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Cardiovascular disease: risk assessment and reduction, including lipid modification
Guideline recommendation text consulted
Publication details
- Issuing organisation
- NICE
- First published
- 14 December 2023
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.